Forest Labs Delays Lung Disease Drug Filing

Forest Laboratories and Almirall announced that they are delaying filing for FDA approval for their combination Tudorza and formoterol drug for chronic obstructive pulmonary disease. The delay, the companies said, is due to issues in chemistry, manufacturing and controls.
Bloomberg Business Week